Paper Details

  1. Home
  2. Paper Details

Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.

Author: , AmicoK Rivet, AndersonPeter L, BekkerLinda-Gail, DyeBonnie J, ElharrarVanessa, EshlemanSusan H, GrantRobert M, HendrixCraig W, HughesJames P, LiMaoji, MarzinkeMark A, McKinstryLaura, Piwowar-ManningEstelle, RooneyJames F, RouxSurita, SebastienElaine, StirrattMichael, YolaNtando

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized, open-label, phase 2 clinical trial investigated the feasibility of non-daily regimens of oral HIV pre-exposure prophylaxis (PrEP) in adult women. The study found that daily PrEP dosing resulted in higher coverage of sex events, increased adherence to the regimen, and augmented drug concentrations than did time-driven or event-driven dosing.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The relative feasibility and acceptability of daily versus non-daily dosing of oral HIV pre-exposure prophylaxis (PrEP) among women are unknown. We aimed to investigate the feasibility of non-daily PrEP regimens in adult women. METHODS: We did a randomised, open-label, phase 2 clinical ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28986029

データ提供：米国国立医学図書館（NLM）

PrEP: A Camel's Guide to Navigating the Desert of HIV Prevention

The global battle against HIV is a relentless fight, and research is constantly exploring new ways to prevent infection. This study focuses on the effectiveness of pre-exposure prophylaxis (PrEP), a medication that can significantly reduce the risk of HIV transmission. The researchers investigate the feasibility of different dosing regimens for PrEP, specifically daily versus non-daily options, among women in South Africa.

The study found that daily PrEP dosing resulted in higher coverage of sexual encounters, improved adherence to the regimen, and higher drug concentrations. This suggests that daily dosing is a more effective strategy for HIV prevention compared to non-daily regimens.

A Steady Path: The Importance of Daily PrEP

The research highlights the importance of adherence to PrEP regimens for optimal effectiveness. Daily dosing offers a more reliable and consistent method for protecting against HIV transmission.

Taking Charge of Your Health: A Camel's Perspective

This research reinforces the importance of making informed decisions about your health. PrEP can be a powerful tool for HIV prevention, but it's crucial to discuss your options with your doctor and find a regimen that best suits your needs. Just as a camel seeks out the best routes across the desert, we must be proactive in our healthcare journey.

Dr. Camel's Conclusion

This study sheds light on the importance of finding the right path in HIV prevention. Daily PrEP offers a robust strategy for reducing the risk of infection, but open communication with your healthcare provider is key. Just as a camel relies on its compass to navigate the desert, we must seek guidance and information to make informed decisions about our health.

Date :
  1. Date Completed 2018-09-19
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

28986029

DOI: Digital Object Identifier

NIHMS956743

Related Literature

Article Analysis
・Side Effects of emtricitabine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.